Fujian-based Chinese pharmaceutical maker, per its industry classification; specific product portfolio not independently confirmed.
Fujian-based Chinese pharmaceutical maker, per its industry classification; specific product portfolio not independently confirmed.
Moat: none
Headquarters: Fujian, China · Employees: 200
Size Fujian Haixi Pharmaceuticals (2637.HK) is a Hong Kong Health Care company (Biotechnology) with a market value of $1.47B, the 481st largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$148.80 on 18 Nov 2026.
Performance Over six months the shares fell 32.3%, against -14.1% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 6th lowest of 20 in its peer set.
Growth Revenue grew 24.8% over the last twelve months (peer median +28.0%); the operating margin is 33.0% (peer median -56.7%).
Valuation It trades at 46.4× forward earnings against a peer median of 16.7× (3rd most expensive of 6).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | n/a | HK$632M | HK$506M | HK$350M | HK$247M |
| Revenue growth | — | +25% | +45% | +42% | — |
| Gross profit | n/a | HK$527M | HK$415M | HK$291M | HK$200M |
| EBITDA | n/a | HK$217M | HK$149M | HK$136M | HK$96.5M |
| Net income | n/a | HK$192M | HK$148M | HK$130M | HK$80.2M |
| Free cash flow | n/a | HK$109M | -HK$30.4M | HK$85.6M | HK$45.3M |
| Capital expenditure | n/a | HK$48.7M | HK$194M | HK$65.7M | HK$36.9M |
| Total debt | n/a | HK$123M | HK$71.2M | HK$55.1M | HK$103M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 2637.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -1.4% | -14.8% | 5th highest of 21 |
| 6-month return | -32.3% | -14.1% | 6th lowest of 20 |
| Distance from 52-week high | -50.8% | -44.6% | 7th lowest of 21 |
| Revenue growth (TTM) | +24.8% | +28.0% | 9th lowest of 18 |
| Operating margin | 33.0% | -56.7% | 3rd highest of 19 |
| Forward P/E | 46.4× | 16.7× | 3rd most expensive of 6 |
| Net debt / EBITDA | -6.3× | 0.9× | least indebted of 4 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Fujian Haixi Pharmaceuticals 2637.HK | Hong Kong | $1.47B | -32% | +25% | 33% | 46.4× | n/a | n/a |
| UroGen Pharma URGN | United States | $1.46B | -1% | +159% | -12% | 16.7× | n/a | n/a |
| Wuhan Healthgen Biotechnology 688765.SS | China | $1.46B | -51% | +90% | -297% | n/a | n/a | n/a |
| Mesoblast MSB.AX | Australia | $1.49B | -17% | +556% | -43% | n/a | n/a | n/a |
| Peptron 087010.KS | South Korea | $1.49B | -68% | -13% | -488% | n/a | n/a | n/a |
| Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh IMCR | United States | $1.44B | -7% | +13% | -7% | n/a | n/a | n/a |
| TLC BioSciences 7924.TWO | Taiwan | $1.50B | n/a | n/a | n/a | n/a | n/a | n/a |
| Chengdu Olymvax Biopharmaceuticals 688319.SS | China | $1.51B | -37% | +12% | 8% | n/a | n/a | n/a |
| Nanjing Vazyme Biotech 688105.SS | China | $1.42B | +25% | +16% | -5% | 137.8× | 39.4% | -2.5% |
| uniQure QURE | United States | $1.42B | -17% | +28% | -1,027% | n/a | n/a | n/a |
| Korsana Biosciences KRSA | United States | $1.52B | +54% | -64% | -5,277% | n/a | n/a | n/a |
| Absci ABSI | United States | $1.41B | +65% | -47% | -9,155% | n/a | n/a | n/a |
| Kailera Therapeutics KLRA | United States | $1.53B | -41% | n/a | n/a | n/a | n/a | n/a |
| Precigen PGEN | United States | $1.53B | 0% | +2,388% | 21% | 7.3× | n/a | n/a |
| AnaptysBio ANAB | United States | $1.40B | -22% | +13% | 62% | 4.9× | 0.5% | +25.6% |
| Nurix Therapeutics NRIX | United States | $1.54B | -14% | +739% | 41% | n/a | n/a | n/a |
| Rapport Therapeutics RAPP | United States | $1.39B | -34% | n/a | -838% | n/a | n/a | n/a |
| CanSino Biologics 688185.SS | China | $1.38B | 0% | +30% | -4% | 199.3× | n/a | n/a |
| Vir Biotechnology VIR | United States | $1.57B | +3% | +1,696% | -70% | n/a | n/a | n/a |
| Oncolys BioPharma 4588.T | Japan | $1.37B | +181% | +1,749% | -295% | n/a | n/a | n/a |
| Intellia Therapeutics NTLA | United States | $1.37B | -20% | -8% | -821% | n/a | n/a | n/a |